Navigation Links
Broad Spectrum Antibiotic Available for Antibiotic Resistant Bacteria

Tygacil (tigecycline)is a new, expanded broad-spectrum IV antibiotic that can be used for the treatment of a wide range of infections including those caused by antibiotic// resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). It will be available in the UK from today. Availability of this new antibiotic comes at a time when the need for effective new treatments is greater than ever and clinicians are running out of options.

"Difficult to treat, antibiotic-resistant and often life-threatening infections are a growing problem in the UK, costing the NHS an estimated additional £1 billion annually," says Dr Robert Masterton, Executive Medical Director and Consultant Microbiologist, NHS Ayrshire & Arran, "Even more worrying has been the emergence of the organisms commonly called 'superbugs' – those very worrying bacteria that have become resistant to a large number and in some cases all available antibiotics. Add to this the diminishing development of new antibiotics in the last 20 years and we could soon see a return to the Florence Nightingale era where infections caused more death than bullets because there were no effective drugs to treat these diseases. The introduction of tigecycline in the UK comes at absolutely the right time and will provide a vital new weapon in the fight against infection."

Tigecycline has been licensed for use in the UK as a treatment for a variety of complicated skin and soft tissue infections including infected wounds and complicated intra- abdominal infections such as complicated appendicitis.1 It is the world's first glycylcycline and has been developed by Wyeth to overcome two common mechanisms of resistance that have reduced the efficacy and limited the use of certain existing antibiotics.

While MRSA has received wide media and government attention and concern in the UK, other infections like Escherichia Coli (E. Coli) and Klebsiella could pose an even greater risk to public health.4, 5 Tigecycline is one of a few new antibiotics with measured activity against these bacteria6 and there are few other antibiotics with a similar spectrum of activity expected this decade.

"Until now, the lack of available antibiotic options for these more difficult to treat bacteria has necessitated the use of combination therapies – two or more different antibiotics – to fight the resistant bacteria," explains Dr Mark Palazzo, Chief of Service for Critical Care Medicine at Hammersmith Hospitals NHS Trust, "Combination treatment can contribute to increased drug costs, drug interactions, with potentially higher patient risk and further increased antibiotic resistance which complicates the treatment. It would be an advantage for patient care to have the option of a new single effective therapy" he concludes.

Serious infections treated in the hospital are a major cause of morbidity and death among hospitalised patients worldwide.7 In the UK alone, hospital-acquired infections (HAIs) account for a staggering 5,000 deaths per year.8 It is estimated that these infections affect just over 300,000 patients every year9 with about nine per cent of hospital patients having a HAI at any one time.

Tigecycline was licensed by the European Commission for use in Europe on 24th April 2006 and is available in the UK today. Tigecycline is indicated for the treatment of complicated infections of the skin and soft tissue and complicated intra-abdominal infections.1 Tigecycline is supported by comprehensive global in vitro studies and an in vivo clinical trials programme.

The most common adverse events reported in clinical trials with tigecycline were nausea and vomiting. These occurred early in the treatment and were generally mild or moderate in severity.

Source : Eurekaert
'"/>




Related medicine news :

1. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
2. Plan To Connect Remote Aboriginal Communities Through Broadband
3. Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc
4. FDA Announces Audio Broadcasts on Emerging Drug Safety Information
5. Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit
6. Simple Eye Movement Test For Early Detection Of Fetal Alcohol Spectrum Disorder
7. Lack Of Social Skills Linked To Autism Spectrum Disorder (ASD)
8. Fetal Alcohol Spectrum Disorder in Children Can Be Diagnosed With Eye Movement Tests
9. Younger Siblings of Children With Autism Spectrum Disorders Score Low
10. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
11. Antibiotics Helps Autism
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/23/2017)... ... January 23, 2017 , ... The Masters of ... and evaluation leaders with decades of experience who remain current practitioners in the ... healthcare system, there is a renewed demand for versatile, data-driven leadership.The American University’s ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... applications. However, choosing the right method is paramount to success. Selecting an inappropriate ... in situations where multiple persons use the same equipment. Rare or expensive substances ...
(Date:1/23/2017)... ... January 23, 2017 , ... Gynecology Associates of Gwinnett (GAoG) ... services for women of all ages. The staff of Gynecology Associates of ... services from routine health screenings to diagnosing and treating female concerns including menopause, ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring ... creation of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. ... over nineteen, a pastor for over fifteen years. He is a graduate of N.C. ...
(Date:1/22/2017)... , ... January 22, 2017 , ... Medical lab ... results. Often the results of a simple test will take days to arrive to ... Test Now offers customers direct access to their lab tests, bypassing the cost and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... -- Ahead of today,s trading session, Stock-Callers.com draws investors, ... at the close: Kite Pharma Inc. (NASDAQ: KITE ), ... and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). According to ... Friday, January 20 th , 2017, down on the day by ... stocks now at: ...
(Date:1/23/2017)... 23 janvier 2017  ResMed (NYSE : RMD), BMC (Pékin, ... ont annoncé aujourd,hui qu,ils se sont mis d,accord sur ... les parties. BMC et 3B seront autorisés à vendre ... à ResMed, et ResMed effectuera le paiement de la ... le litige de Floride entre les deux parties. Le ...
(Date:1/23/2017)... remain until legal experts and senior industry leaders involved in supply chain, ... to discuss the flow of pharmaceutical products post Brexit at the only ... In the run up to the show, SMi Group have ... the event download centre . ... Some of those confirmed include: EMA, Aeterna Zentaris, ...
Breaking Medicine Technology: